Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency.
about
International Consensus Document (ICON): Common Variable Immunodeficiency DisordersHealth-related quality of life in patients with primary immunodeficiency diseaseSubcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections.Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency.Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy.Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases.Immunoglobulin replacement therapy in children.Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.Common infusion-related reactions to subcutaneous immunoglobulin therapy: Managing patient expectationsSubcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease.Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.A cohort of French pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions?A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis.Clinical experiences in primary and secondary immunodeficiencies and immune-mediated conditions using Gammanorm(®).Dose-related regulatory effect of intravenous immunoglobulin on dendritic cells-mediated immune response.Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina.Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies.Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies.Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes.Dosing and therapy utilization: a discussion of updates on PI treatment guidelines.Quality of Life, Treatment Beliefs, and Treatment Satisfaction in Children Treated for Primary Immunodeficiency with SCIg.
P2860
Q26777304-40572C7C-6A2B-4F3E-9CDD-094F3AB98D64Q26784167-4965C801-2AD7-4B27-A63D-5B42149C2E7AQ33635013-86DED25D-B0D3-487C-81B5-19E92742145CQ33692418-659A222D-0B5D-4F71-AAF1-F521343FDA84Q34992090-D2271E68-1384-4B89-BEBC-369CB225D3F8Q35959163-4E63729F-5FBD-4AC7-8D31-0A5AC7AB96DBQ36121067-2D966532-A9E9-4C78-B8F5-0DA1392C285BQ36196688-C024A27A-1545-4980-A454-8F17A85B5389Q36979273-1B28EAFA-6261-42C1-B87C-51C9A51C6588Q37031111-1D1374D6-50CC-4DF4-A816-028615182748Q37083973-DEDE2507-534B-4886-B7EC-35878862CF80Q37405485-A78D0E3B-47FA-41A8-AEAA-13EFBA622C9CQ37890936-DA535BDA-5FCE-4DBB-AF70-C1B579578839Q38021422-A1A6FDCB-B3E2-4A3F-B535-896A9E15965DQ38122120-C17022DE-CAE1-499A-83B1-53661F0F6E75Q38266635-A2C2E096-F8E1-4CF5-9E73-FC5C3D7105EFQ38390889-928E4C3B-EC2A-42D9-A8C5-5BDCB97B8E47Q38661420-B979D635-D16D-49B2-BB54-DBE437B9F266Q38744512-432981A5-ABD6-46D9-82DC-0A00CF653E15Q39217483-4F719298-6ACB-43E7-949B-15140581D3CAQ42251007-4E17E18E-E137-4832-AC06-5327E8C0A208Q42608614-EF734253-A827-493C-806A-A9912E53CFE1Q42694622-36947993-4977-450C-86D2-1203BDF85161Q44050973-27797193-2666-41E6-B3BF-7D1966AC6330Q46004431-EEE0AFBD-28E4-47A0-988B-482AFCAF4B13Q46048428-D609A642-2EE6-454E-8CFA-4E431DFB39A5Q48302996-D5EE135F-860C-42A8-8EAE-54F0DC1AB260
P2860
Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Safety and efficacy of subcuta ...... with primary immunodeficiency.
@en
Safety and efficacy of subcuta ...... with primary immunodeficiency.
@nl
type
label
Safety and efficacy of subcuta ...... with primary immunodeficiency.
@en
Safety and efficacy of subcuta ...... with primary immunodeficiency.
@nl
prefLabel
Safety and efficacy of subcuta ...... with primary immunodeficiency.
@en
Safety and efficacy of subcuta ...... with primary immunodeficiency.
@nl
P2860
P1433
P1476
Safety and efficacy of subcuta ...... with primary immunodeficiency.
@en
P2093
Jeanette Nyström
P2860
P304
P356
10.1111/J.1651-2227.2007.00485.X
P407
P50
P577
2007-09-10T00:00:00Z